ReproductiveFDA Approved

Cetrorelix (Cetrotide) Analog

Subcutaneous injection

Overview

Cetrorelix is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) that acts as a competitive GnRH receptor antagonist. By binding to pituitary GnRH receptors, it rapidly suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion without the initial agonist flare seen with GnRH agonists.

Mechanism of Action

This property makes it valuable for controlled ovarian stimulation protocols, where prevention of premature LH surges is critical for optimizing oocyte retrieval timing..

Research Summary & Key Findings

Cetrorelix acetate was approved by the FDA in 2000 for prevention of premature LH surges in women undergoing controlled ovarian stimulation. Multiple randomized controlled trials have demonstrated comparable pregnancy rates to GnRH agonist protocols while allowing shorter treatment duration and reduced gonadotropin requirements.

Clinical Status

FDA Approved

Cetrorelix (Cetrotide) Analog has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection

Related Peptides in Reproductive

Find a Provider

Find a verified provider who offers Cetrorelix (Cetrotide) Analog therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Cetrorelix (Cetrotide) Analog.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.